Oral CUDC-101: Phase I started

Curis began a dose-escalation, U.S. Phase I trial to evaluate 200-500 mg oral CUDC-101 twice daily in 21-day cycles in about 36 patients with advanced or refractory solid tumors. Curis has completed a...